glp-1 drug exposure pharmaceutical companies 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.) GLP-1 Market Trends and Global
Description
Animal studies have shown that GLP-1 promotes neogenesis and cell proliferation, inhibits apoptosis, and increases the mass of cells [6]
The FLOW trial, the first kidney-outcomes study built specifically around a GLP-1 drug, was stopped early after independent monitors found clear evidence of kidney benefit a rare and telling signal in clinical research [7]
J Biol Chem 175, 663674 (1948)
1 Previously, multiple other GLP-1 agonists reached the public (Table 1)
Relative to placebo, the reduction of diastolic BP only reached significance for the treatment of exenatide 10 g/twice daily (1.08 mmHg) [620]
Research has focused on small-molecule GLP-1R agonists because of their ease of use in oral formulations and improved patient compliance
